ISRCTN87769578 https://doi.org/10.1186/ISRCTN87769578

Ultrasound therapy for plantar fasciitis. A double blind randomised placebo controlled trial

Submission date
12/09/2003

Recruitment status
No longer recruiting

Registration date
12/09/2003

Overall study status
Completed

Last Edited
15/05/2012

Condition category
Musculoskeletal Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[X] Results
[ ] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Cathy Speed

Contact details
Box No 204
Department of Rheumatology
Addenbrooke's NHS Trust
Hills Road
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 586518
cathy.speed@btinternet.com

Additional identifiers

Protocol serial number
N0544093542

Study information

Scientific Title

Study objectives
Ultrasound in plantar fasciitis.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Musculoskeletal Diseases: Plantar fasciitis

Interventions
To evaluate the effects of ultrasound in the treatment of plantar fasciitis. Adult subjects with plantar fasciitis will be randomised to receive either ultrasound (US) or sham (S) therapy. In the US group pulsed ultrasound will be delivered at a standardised dosage, initially five times weekly for 3 weeks, then three times weekly for 3 weeks. A single machine will be used and calibrated twice daily. The patient, assessor and treating clinician will all be blinded. Outcome measures will be recorded at 6 weeks and at 4 months from baseline. These will include an ankle and foot score and pain (primary measures), isokinetic strength of ankle plantar flexion and dorsifexion, flexibility, inflammation (thermographic score), quality of life and general health status, a summary item of status of the injury and a follow up transition item.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
12/10/2003

Eligibility

Key inclusion criteria
200 (PROJ)

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Does not meet inclusion criteria

Date of first enrolment
12/10/2000

Date of final enrolment
12/10/2003

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Box No 204
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation
Department of Health (UK)

Funder(s)

Funder type
Other

Funder Name
Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2003		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes